Immunome, Inc. (IMNM) shares soared 6.1% in the last trading session to close at $11.2. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 3.9% gain over the past four weeks.The sudden price rise can be attributed to growing investor optimism regarding the company’s efforts to develop its lead pipeline candidate, varegacestat, which is currently being evaluated in a late-stage study for the treatment of desmoid tumors. Immunome is a ...